The global Hemophilia A Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Hemophilia A Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia A Drug.

Report Scope

The Hemophilia A Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hemophilia A Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hemophilia A Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Hemophilia A Drug Market Report

Report Metric	Details
Report Name	Hemophilia A Drug Market
CAGR	5%
Segment by Type	ATXF-8117 BAY-1093884 BIVV-001 BS-027125 Concizumab CSL-689 Others
Segment by Application	Clinic Hospital ASCs
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Bayer AG, BioMarin Pharmaceutical Inc, Bioverativ Inc, Catalyst Biosciences Inc, Chugai Pharmaceutical Co Ltd, CSL Ltd, DBV Technologies SA, Dimension Therapeutics Inc, EpiVax Inc, Expression Therapeutics LLC, Green Cross Corp, Idogen AB, Immusoft Corp, LFB SA, mAbxience SA
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hemophilia A Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hemophilia A Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Hemophilia A Drug Market report?

Ans: The main players in the Hemophilia A Drug Market are Bayer AG, BioMarin Pharmaceutical Inc, Bioverativ Inc, Catalyst Biosciences Inc, Chugai Pharmaceutical Co Ltd, CSL Ltd, DBV Technologies SA, Dimension Therapeutics Inc, EpiVax Inc, Expression Therapeutics LLC, Green Cross Corp, Idogen AB, Immusoft Corp, LFB SA, mAbxience SA

What are the Application segmentation covered in the Hemophilia A Drug Market report?

Ans: The Applications covered in the Hemophilia A Drug Market report are Clinic, Hospital, ASCs

What are the Type segmentation covered in the Hemophilia A Drug Market report?

Ans: The Types covered in the Hemophilia A Drug Market report are ATXF-8117, BAY-1093884, BIVV-001, BS-027125, Concizumab, CSL-689, Others

1 Hemophilia A Drug Market Overview

1.1 Product Overview and Scope of Hemophilia A Drug

1.2 Hemophilia A Drug Segment by Type

1.2.1 Global Hemophilia A Drug Market Value Comparison by Type (2024-2030)

1.2.2 ATXF-8117

1.2.3 BAY-1093884

1.2.4 BIVV-001

1.2.5 BS-027125

1.2.6 Concizumab

1.2.7 CSL-689

1.2.8 Others

1.3 Hemophilia A Drug Segment by Application

1.3.1 Global Hemophilia A Drug Market Value by Application: (2024-2030)

1.3.2 Clinic

1.3.3 Hospital

1.3.4 ASCs

1.4 Global Hemophilia A Drug Market Size Estimates and Forecasts

1.4.1 Global Hemophilia A Drug Revenue 2019-2030

1.4.2 Global Hemophilia A Drug Sales 2019-2030

1.4.3 Global Hemophilia A Drug Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Hemophilia A Drug Market Competition by Manufacturers

2.1 Global Hemophilia A Drug Sales Market Share by Manufacturers (2019-2024)

2.2 Global Hemophilia A Drug Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Hemophilia A Drug Average Price by Manufacturers (2019-2024)

2.4 Global Hemophilia A Drug Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Hemophilia A Drug, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Hemophilia A Drug, Product Type & Application

2.7 Hemophilia A Drug Market Competitive Situation and Trends

2.7.1 Hemophilia A Drug Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Hemophilia A Drug Players Market Share by Revenue

2.7.3 Global Hemophilia A Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Hemophilia A Drug Retrospective Market Scenario by Region

3.1 Global Hemophilia A Drug Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Hemophilia A Drug Global Hemophilia A Drug Sales by Region: 2019-2030

3.2.1 Global Hemophilia A Drug Sales by Region: 2019-2024

3.2.2 Global Hemophilia A Drug Sales by Region: 2025-2030

3.3 Global Hemophilia A Drug Global Hemophilia A Drug Revenue by Region: 2019-2030

3.3.1 Global Hemophilia A Drug Revenue by Region: 2019-2024

3.3.2 Global Hemophilia A Drug Revenue by Region: 2025-2030

3.4 North America Hemophilia A Drug Market Facts & Figures by Country

3.4.1 North America Hemophilia A Drug Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Hemophilia A Drug Sales by Country (2019-2030)

3.4.3 North America Hemophilia A Drug Revenue by Country (2019-2030)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Hemophilia A Drug Market Facts & Figures by Country

3.5.1 Europe Hemophilia A Drug Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Hemophilia A Drug Sales by Country (2019-2030)

3.5.3 Europe Hemophilia A Drug Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Hemophilia A Drug Market Facts & Figures by Country

3.6.1 Asia Pacific Hemophilia A Drug Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Hemophilia A Drug Sales by Country (2019-2030)

3.6.3 Asia Pacific Hemophilia A Drug Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Hemophilia A Drug Market Facts & Figures by Country

3.7.1 Latin America Hemophilia A Drug Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Hemophilia A Drug Sales by Country (2019-2030)

3.7.3 Latin America Hemophilia A Drug Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Hemophilia A Drug Market Facts & Figures by Country

3.8.1 Middle East and Africa Hemophilia A Drug Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Hemophilia A Drug Sales by Country (2019-2030)

3.8.3 Middle East and Africa Hemophilia A Drug Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Hemophilia A Drug Sales by Type (2019-2030)

4.1.1 Global Hemophilia A Drug Sales by Type (2019-2024)

4.1.2 Global Hemophilia A Drug Sales by Type (2025-2030)

4.1.3 Global Hemophilia A Drug Sales Market Share by Type (2019-2030)

4.2 Global Hemophilia A Drug Revenue by Type (2019-2030)

4.2.1 Global Hemophilia A Drug Revenue by Type (2019-2024)

4.2.2 Global Hemophilia A Drug Revenue by Type (2025-2030)

4.2.3 Global Hemophilia A Drug Revenue Market Share by Type (2019-2030)

4.3 Global Hemophilia A Drug Price by Type (2019-2030)

5 Segment by Application

5.1 Global Hemophilia A Drug Sales by Application (2019-2030)

5.1.1 Global Hemophilia A Drug Sales by Application (2019-2024)

5.1.2 Global Hemophilia A Drug Sales by Application (2025-2030)

5.1.3 Global Hemophilia A Drug Sales Market Share by Application (2019-2030)

5.2 Global Hemophilia A Drug Revenue by Application (2019-2030)

5.2.1 Global Hemophilia A Drug Revenue by Application (2019-2024)

5.2.2 Global Hemophilia A Drug Revenue by Application (2025-2030)

5.2.3 Global Hemophilia A Drug Revenue Market Share by Application (2019-2030)

5.3 Global Hemophilia A Drug Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Bayer AG

6.1.1 Bayer AG Corporation Information

6.1.2 Bayer AG Description and Business Overview

6.1.3 Bayer AG Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Bayer AG Hemophilia A Drug Product Portfolio

6.1.5 Bayer AG Recent Developments/Updates

6.2 BioMarin Pharmaceutical Inc

6.2.1 BioMarin Pharmaceutical Inc Corporation Information

6.2.2 BioMarin Pharmaceutical Inc Description and Business Overview

6.2.3 BioMarin Pharmaceutical Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.2.4 BioMarin Pharmaceutical Inc Hemophilia A Drug Product Portfolio

6.2.5 BioMarin Pharmaceutical Inc Recent Developments/Updates

6.3 Bioverativ Inc

6.3.1 Bioverativ Inc Corporation Information

6.3.2 Bioverativ Inc Description and Business Overview

6.3.3 Bioverativ Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Bioverativ Inc Hemophilia A Drug Product Portfolio

6.3.5 Bioverativ Inc Recent Developments/Updates

6.4 Catalyst Biosciences Inc

6.4.1 Catalyst Biosciences Inc Corporation Information

6.4.2 Catalyst Biosciences Inc Description and Business Overview

6.4.3 Catalyst Biosciences Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Catalyst Biosciences Inc Hemophilia A Drug Product Portfolio

6.4.5 Catalyst Biosciences Inc Recent Developments/Updates

6.5 Chugai Pharmaceutical Co Ltd

6.5.1 Chugai Pharmaceutical Co Ltd Corporation Information

6.5.2 Chugai Pharmaceutical Co Ltd Description and Business Overview

6.5.3 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Product Portfolio

6.5.5 Chugai Pharmaceutical Co Ltd Recent Developments/Updates

6.6 CSL Ltd

6.6.1 CSL Ltd Corporation Information

6.6.2 CSL Ltd Description and Business Overview

6.6.3 CSL Ltd Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.6.4 CSL Ltd Hemophilia A Drug Product Portfolio

6.6.5 CSL Ltd Recent Developments/Updates

6.7 DBV Technologies SA

6.6.1 DBV Technologies SA Corporation Information

6.6.2 DBV Technologies SA Description and Business Overview

6.6.3 DBV Technologies SA Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.4.4 DBV Technologies SA Hemophilia A Drug Product Portfolio

6.7.5 DBV Technologies SA Recent Developments/Updates

6.8 Dimension Therapeutics Inc

6.8.1 Dimension Therapeutics Inc Corporation Information

6.8.2 Dimension Therapeutics Inc Description and Business Overview

6.8.3 Dimension Therapeutics Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Dimension Therapeutics Inc Hemophilia A Drug Product Portfolio

6.8.5 Dimension Therapeutics Inc Recent Developments/Updates

6.9 EpiVax Inc

6.9.1 EpiVax Inc Corporation Information

6.9.2 EpiVax Inc Description and Business Overview

6.9.3 EpiVax Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.9.4 EpiVax Inc Hemophilia A Drug Product Portfolio

6.9.5 EpiVax Inc Recent Developments/Updates

6.10 Expression Therapeutics LLC

6.10.1 Expression Therapeutics LLC Corporation Information

6.10.2 Expression Therapeutics LLC Description and Business Overview

6.10.3 Expression Therapeutics LLC Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Expression Therapeutics LLC Hemophilia A Drug Product Portfolio

6.10.5 Expression Therapeutics LLC Recent Developments/Updates

6.11 Green Cross Corp

6.11.1 Green Cross Corp Corporation Information

6.11.2 Green Cross Corp Hemophilia A Drug Description and Business Overview

6.11.3 Green Cross Corp Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Green Cross Corp Hemophilia A Drug Product Portfolio

6.11.5 Green Cross Corp Recent Developments/Updates

6.12 Idogen AB

6.12.1 Idogen AB Corporation Information

6.12.2 Idogen AB Hemophilia A Drug Description and Business Overview

6.12.3 Idogen AB Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Idogen AB Hemophilia A Drug Product Portfolio

6.12.5 Idogen AB Recent Developments/Updates

6.13 Immusoft Corp

6.13.1 Immusoft Corp Corporation Information

6.13.2 Immusoft Corp Hemophilia A Drug Description and Business Overview

6.13.3 Immusoft Corp Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Immusoft Corp Hemophilia A Drug Product Portfolio

6.13.5 Immusoft Corp Recent Developments/Updates

6.14 LFB SA

6.14.1 LFB SA Corporation Information

6.14.2 LFB SA Hemophilia A Drug Description and Business Overview

6.14.3 LFB SA Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.14.4 LFB SA Hemophilia A Drug Product Portfolio

6.14.5 LFB SA Recent Developments/Updates

6.15 mAbxience SA

6.15.1 mAbxience SA Corporation Information

6.15.2 mAbxience SA Hemophilia A Drug Description and Business Overview

6.15.3 mAbxience SA Hemophilia A Drug Sales, Revenue and Gross Margin (2019-2024)

6.15.4 mAbxience SA Hemophilia A Drug Product Portfolio

6.15.5 mAbxience SA Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Hemophilia A Drug Industry Chain Analysis

7.2 Hemophilia A Drug Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Hemophilia A Drug Production Mode & Process

7.4 Hemophilia A Drug Sales and Marketing

7.4.1 Hemophilia A Drug Sales Channels

7.4.2 Hemophilia A Drug Distributors

7.5 Hemophilia A Drug Customers

8 Hemophilia A Drug Market Dynamics

8.1 Hemophilia A Drug Industry Trends

8.2 Hemophilia A Drug Market Drivers

8.3 Hemophilia A Drug Market Challenges

8.4 Hemophilia A Drug Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Bayer

BioMarin Pharmaceutical Inc

Bioverativ

Catalyst Biosciences Inc

Chugai Pharmaceutical Co., Ltd.

CSL Limited

DBV Technologies SA

Dimension Therapeutics Inc

EpiVax

Expression Therapeutics LLC

List of Tables

Table 1. Global Hemophilia A Drug Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Hemophilia A Drug Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Hemophilia A Drug Market Competitive Situation by Manufacturers in 2023

Table 4. Global Hemophilia A Drug Sales (K Pcs) of Key Manufacturers (2019-2024)

Table 5. Global Hemophilia A Drug Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Hemophilia A Drug Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Hemophilia A Drug Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Hemophilia A Drug Average Price (USD/Pcs) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Hemophilia A Drug, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Hemophilia A Drug, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Hemophilia A Drug, Product Type & Application

Table 12. Global Key Manufacturers of Hemophilia A Drug, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Hemophilia A Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hemophilia A Drug as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Hemophilia A Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Hemophilia A Drug Sales by Region (2019-2024) & (K Pcs)

Table 18. Global Hemophilia A Drug Sales Market Share by Region (2019-2024)

Table 19. Global Hemophilia A Drug Sales by Region (2025-2030) & (K Pcs)

Table 20. Global Hemophilia A Drug Sales Market Share by Region (2025-2030)

Table 21. Global Hemophilia A Drug Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Hemophilia A Drug Revenue Market Share by Region (2019-2024)

Table 23. Global Hemophilia A Drug Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Hemophilia A Drug Revenue Market Share by Region (2025-2030)

Table 25. North America Hemophilia A Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Hemophilia A Drug Sales by Country (2019-2024) & (K Pcs)

Table 27. North America Hemophilia A Drug Sales by Country (2025-2030) & (K Pcs)

Table 28. North America Hemophilia A Drug Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Hemophilia A Drug Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Hemophilia A Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Hemophilia A Drug Sales by Country (2019-2024) & (K Pcs)

Table 32. Europe Hemophilia A Drug Sales by Country (2025-2030) & (K Pcs)

Table 33. Europe Hemophilia A Drug Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Hemophilia A Drug Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Hemophilia A Drug Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Hemophilia A Drug Sales by Region (2019-2024) & (K Pcs)

Table 37. Asia Pacific Hemophilia A Drug Sales by Region (2025-2030) & (K Pcs)

Table 38. Asia Pacific Hemophilia A Drug Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Hemophilia A Drug Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Hemophilia A Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Hemophilia A Drug Sales by Country (2019-2024) & (K Pcs)

Table 42. Latin America Hemophilia A Drug Sales by Country (2025-2030) & (K Pcs)

Table 43. Latin America Hemophilia A Drug Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Hemophilia A Drug Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Hemophilia A Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Hemophilia A Drug Sales by Country (2019-2024) & (K Pcs)

Table 47. Middle East & Africa Hemophilia A Drug Sales by Country (2025-2030) & (K Pcs)

Table 48. Middle East & Africa Hemophilia A Drug Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Hemophilia A Drug Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Hemophilia A Drug Sales (K Pcs) by Type (2019-2024)

Table 51. Global Hemophilia A Drug Sales (K Pcs) by Type (2025-2030)

Table 52. Global Hemophilia A Drug Sales Market Share by Type (2019-2024)

Table 53. Global Hemophilia A Drug Sales Market Share by Type (2025-2030)

Table 54. Global Hemophilia A Drug Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Hemophilia A Drug Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Hemophilia A Drug Revenue Market Share by Type (2019-2024)

Table 57. Global Hemophilia A Drug Revenue Market Share by Type (2025-2030)

Table 58. Global Hemophilia A Drug Price (USD/Pcs) by Type (2019-2024)

Table 59. Global Hemophilia A Drug Price (USD/Pcs) by Type (2025-2030)

Table 60. Global Hemophilia A Drug Sales (K Pcs) by Application (2019-2024)

Table 61. Global Hemophilia A Drug Sales (K Pcs) by Application (2025-2030)

Table 62. Global Hemophilia A Drug Sales Market Share by Application (2019-2024)

Table 63. Global Hemophilia A Drug Sales Market Share by Application (2025-2030)

Table 64. Global Hemophilia A Drug Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Hemophilia A Drug Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Hemophilia A Drug Revenue Market Share by Application (2019-2024)

Table 67. Global Hemophilia A Drug Revenue Market Share by Application (2025-2030)

Table 68. Global Hemophilia A Drug Price (USD/Pcs) by Application (2019-2024)

Table 69. Global Hemophilia A Drug Price (USD/Pcs) by Application (2025-2030)

Table 70. Bayer AG Corporation Information

Table 71. Bayer AG Description and Business Overview

Table 72. Bayer AG Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 73. Bayer AG Hemophilia A Drug Product

Table 74. Bayer AG Recent Developments/Updates

Table 75. BioMarin Pharmaceutical Inc Corporation Information

Table 76. BioMarin Pharmaceutical Inc Description and Business Overview

Table 77. BioMarin Pharmaceutical Inc Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 78. BioMarin Pharmaceutical Inc Hemophilia A Drug Product

Table 79. BioMarin Pharmaceutical Inc Recent Developments/Updates

Table 80. Bioverativ Inc Corporation Information

Table 81. Bioverativ Inc Description and Business Overview

Table 82. Bioverativ Inc Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 83. Bioverativ Inc Hemophilia A Drug Product

Table 84. Bioverativ Inc Recent Developments/Updates

Table 85. Catalyst Biosciences Inc Corporation Information

Table 86. Catalyst Biosciences Inc Description and Business Overview

Table 87. Catalyst Biosciences Inc Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 88. Catalyst Biosciences Inc Hemophilia A Drug Product

Table 89. Catalyst Biosciences Inc Recent Developments/Updates

Table 90. Chugai Pharmaceutical Co Ltd Corporation Information

Table 91. Chugai Pharmaceutical Co Ltd Description and Business Overview

Table 92. Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 93. Chugai Pharmaceutical Co Ltd Hemophilia A Drug Product

Table 94. Chugai Pharmaceutical Co Ltd Recent Developments/Updates

Table 95. CSL Ltd Corporation Information

Table 96. CSL Ltd Description and Business Overview

Table 97. CSL Ltd Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 98. CSL Ltd Hemophilia A Drug Product

Table 99. CSL Ltd Recent Developments/Updates

Table 100. DBV Technologies SA Corporation Information

Table 101. DBV Technologies SA Description and Business Overview

Table 102. DBV Technologies SA Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 103. DBV Technologies SA Hemophilia A Drug Product

Table 104. DBV Technologies SA Recent Developments/Updates

Table 105. Dimension Therapeutics Inc Corporation Information

Table 106. Dimension Therapeutics Inc Description and Business Overview

Table 107. Dimension Therapeutics Inc Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 108. Dimension Therapeutics Inc Hemophilia A Drug Product

Table 109. Dimension Therapeutics Inc Recent Developments/Updates

Table 110. EpiVax Inc Corporation Information

Table 111. EpiVax Inc Description and Business Overview

Table 112. EpiVax Inc Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 113. EpiVax Inc Hemophilia A Drug Product

Table 114. EpiVax Inc Recent Developments/Updates

Table 115. Expression Therapeutics LLC Corporation Information

Table 116. Expression Therapeutics LLC Description and Business Overview

Table 117. Expression Therapeutics LLC Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 118. Expression Therapeutics LLC Hemophilia A Drug Product

Table 119. Expression Therapeutics LLC Recent Developments/Updates

Table 120. Green Cross Corp Corporation Information

Table 121. Green Cross Corp Description and Business Overview

Table 122. Green Cross Corp Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 123. Green Cross Corp Hemophilia A Drug Product

Table 124. Green Cross Corp Recent Developments/Updates

Table 125. Idogen AB Corporation Information

Table 126. Idogen AB Description and Business Overview

Table 127. Idogen AB Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 128. Idogen AB Hemophilia A Drug Product

Table 129. Idogen AB Recent Developments/Updates

Table 130. Immusoft Corp Corporation Information

Table 131. Immusoft Corp Description and Business Overview

Table 132. Immusoft Corp Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 133. Immusoft Corp Hemophilia A Drug Product

Table 134. Immusoft Corp Recent Developments/Updates

Table 135. LFB SA Corporation Information

Table 136. LFB SA Description and Business Overview

Table 137. LFB SA Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 138. LFB SA Hemophilia A Drug Product

Table 139. LFB SA Recent Developments/Updates

Table 140. mAbxience SA Corporation Information

Table 141. mAbxience SA Description and Business Overview

Table 142. mAbxience SA Hemophilia A Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 143. mAbxience SA Hemophilia A Drug Product

Table 144. mAbxience SA Recent Developments/Updates

Table 145. Key Raw Materials Lists

Table 146. Raw Materials Key Suppliers Lists

Table 147. Hemophilia A Drug Distributors List

Table 148. Hemophilia A Drug Customers List

Table 149. Hemophilia A Drug Market Trends

Table 150. Hemophilia A Drug Market Drivers

Table 151. Hemophilia A Drug Market Challenges

Table 152. Hemophilia A Drug Market Restraints

Table 153. Research Programs/Design for This Report

Table 154. Key Data Information from Secondary Sources

Table 155. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Hemophilia A Drug

Figure 2. Global Hemophilia A Drug Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Hemophilia A Drug Market Share by Type in 2023 & 2030

Figure 4. ATXF-8117 Product Picture

Figure 5. BAY-1093884 Product Picture

Figure 6. BIVV-001 Product Picture

Figure 7. BS-027125 Product Picture

Figure 8. Concizumab Product Picture

Figure 9. CSL-689 Product Picture

Figure 10. Others Product Picture

Figure 11. Global Hemophilia A Drug Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 12. Global Hemophilia A Drug Market Share by Application in 2023 & 2030

Figure 13. Clinic

Figure 14. Hospital

Figure 15. ASCs

Figure 16. Global Hemophilia A Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 17. Global Hemophilia A Drug Market Size (2019-2030) & (US$ Million)

Figure 18. Global Hemophilia A Drug Sales (2019-2030) & (K Pcs)

Figure 19. Global Hemophilia A Drug Average Price (USD/Pcs) & (2019-2030)

Figure 20. Hemophilia A Drug Report Years Considered

Figure 21. Hemophilia A Drug Sales Share by Manufacturers in 2023

Figure 22. Global Hemophilia A Drug Revenue Share by Manufacturers in 2023

Figure 23. The Global 5 and 10 Largest Hemophilia A Drug Players: Market Share by Revenue in 2023

Figure 24. Hemophilia A Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 25. Global Hemophilia A Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 26. North America Hemophilia A Drug Sales Market Share by Country (2019-2030)

Figure 27. North America Hemophilia A Drug Revenue Market Share by Country (2019-2030)

Figure 28. U.S. Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Canada Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Europe Hemophilia A Drug Sales Market Share by Country (2019-2030)

Figure 31. Europe Hemophilia A Drug Revenue Market Share by Country (2019-2030)

Figure 32. Germany Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. France Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. U.K. Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Italy Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Russia Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Asia Pacific Hemophilia A Drug Sales Market Share by Region (2019-2030)

Figure 38. Asia Pacific Hemophilia A Drug Revenue Market Share by Region (2019-2030)

Figure 39. China Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Japan Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. South Korea Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. India Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Australia Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Taiwan Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Indonesia Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Thailand Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Malaysia Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Philippines Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Latin America Hemophilia A Drug Sales Market Share by Country (2019-2030)

Figure 50. Latin America Hemophilia A Drug Revenue Market Share by Country (2019-2030)

Figure 51. Mexico Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Brazil Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Argentina Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. Middle East & Africa Hemophilia A Drug Sales Market Share by Country (2019-2030)

Figure 55. Middle East & Africa Hemophilia A Drug Revenue Market Share by Country (2019-2030)

Figure 56. Turkey Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 57. Saudi Arabia Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 58. UAE Hemophilia A Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 59. Global Sales Market Share of Hemophilia A Drug by Type (2019-2030)

Figure 60. Global Revenue Market Share of Hemophilia A Drug by Type (2019-2030)

Figure 61. Global Hemophilia A Drug Price (USD/Pcs) by Type (2019-2030)

Figure 62. Global Sales Market Share of Hemophilia A Drug by Application (2019-2030)

Figure 63. Global Revenue Market Share of Hemophilia A Drug by Application (2019-2030)

Figure 64. Global Hemophilia A Drug Price (USD/Pcs) by Application (2019-2030)

Figure 65. Hemophilia A Drug Value Chain

Figure 66. Hemophilia A Drug Production Process

Figure 67. Channels of Distribution (Direct Vs Distribution)

Figure 68. Distributors Profiles

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bleeding Disorder Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Research Report 2025

Hematological Malignancies Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Hemorrhagic Shock Treatment Market Research Report 2025

Global Hemoglobinopathies Drugs Market Research Report 2024

Global Anticoagulant Medicine Market Research Report 2025

Sickle Cell Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Diagnostic Guidewire Market Research Report 2024

Global In Vitro Diagnostics IVD Products and Test Market Research Report 2025

Drug Screening Test Kit Market

Global IVD Raw Materials Market Insights Forecast to 2030

Global Hematological Malignancy Treatment Market Research Report 2025

Global Still s Disease Treatment Market Research Report 2025

Global Drugs of Abuse Testing Market Research Report 2024

Global Ant Killer Market Research Report 2024

Global Treatment Planning Software Market Research Report 2025

Hematological Malignancy Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Drugs of Abuse Test Kit Market Research Report 2025

Global Drug Safety and Pharmacovigilance Service Market Research Report 2025

RELATED REPORTS

Global Simvastatin Tablets Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-39P19317

Tue Jun 03 00:00:00 UTC 2025

Add to Cart

Global Anesthesia and Muscle Relaxants Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26U16109

Tue Jun 03 00:00:00 UTC 2025

Add to Cart

Global Dendritic Cell Tumor Treatment Vaccine Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-3T16468

Tue Jun 03 00:00:00 UTC 2025

Add to Cart

Global Fluoroquinolone Antibiotics Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-8J16453

Tue Jun 03 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions